Fig. 4.

Enavatuzumab enhanced the antitumor activity of gemcitabine and navelbine in a triple-negative model of breast cancer. Established MB231 variant xenograft tumors were treated with enavatuzumab at 1 mg/kg thrice weekly, alone or in combination with gemcitabine at 30 mg/kg (a) or vinorelbine at 5 mg/kg (b) twice weekly, with 7 mice in each dosing group. Tumor volumes were measured on gemcitabine and vinorelbine dosing days; points, mean; bars, SEM. Differences in tumor volumes were significant (p < 0.05) between the gemcitabine and enavatuzumab/gemcitabine treatment groups and the vinorelbine and enavatuzumab/vinorelbine treatment groups on days 22–34. The data shown in a and b were derived from a single study. A second study yielded similar results